Micropulse laser for new and hard-to-treat diabetic macular edema
Tests micropulse laser in adults with diabetic macular edema, new or refractory.
Plain-language title generated from the registry record
Registry title: Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema
Key facts
- Where
- Cairo, EgyptSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 1 or type 2 diabetes who have swelling in the centre of the retina (diabetic macular edema), either newly found or not improving with earlier treatment.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- Diabetic macular edema that involves the centre of the retina, with retina thickness above 250 and below 700 µm on a scan. Any level of non-proliferative diabetic retinopathy, or proliferative diabetic retinopathy that has had enough panretinal photocoagulation (PRP) laser and shows no active disease.
- Earlier treatment
- Two groups are studied: people never treated for this swelling and people whose swelling did not improve with earlier treatment. PRP laser within 4 months before the trial, or eye surgery within 6 months, is not allowed.
- Biomarker or test result
- Best-corrected visual acuity of 20/400 or better. HbA1c must not be above 10% (86 mmol/mol).
Main reasons for not taking part
- Only one working eye
- Chronic kidney failure or kidney transplant due to diabetic kidney disease
- HbA1c of more than 10% (86 mmol/mol)
- Traction on the macula, epiretinal membrane, or severe glaucoma
- Eye surgery within 6 months, or PRP laser within 4 months
Read by machine on 12 November 2026.
Where in Egypt
- the General Authority for Teaching Hospitals and InstitutesCairo, EgyptContact: Hossam A Hassan, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The General Authority for Teaching Hospitals and Institutes
- Trial code
- NCT07295704
- Record updated
- 22 December 2025
- Original description
This study aims to evaluate the effect of subthreshold 577 nm micropulse laser photocoagulation in the treatment of initial and refractory cases of Center-Involved Diabetic Macular Edema.Read full original descriptionShow less
Comparative Evaluation of Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema
This study aims to evaluate the effect of subthreshold 577 nm micropulse laser photocoagulation in the treatment of initial and refractory cases of Center-Involved Diabetic Macular Edema.
Inclusion: Age ≥18 years; Both sexes; Patients with type 1 or 2 diabetes mellitus (DM), best-corrected visual acuity (BCVA) of 20/400 or better, and center-involved DME [defined as a central macular thickness (CMT) of >250 but <700µm measured by spectral-domain optical coherence tomography]; Patients with any level of non-proliferative diabetic retinopathy or proliferative diabetic retinopathy with adequate panretinal photocoagulation (PRP) and no signs of disease activity determined by fluorescein angiography (FA).
Exclusion: Intraocular surgery within 6months, including cataract or vitreoretinal operation; Chronic renal failure or renal transplant because of diabetic nephropathy; Vitreomacular traction syndrome; Any condition that could interfere with optical coherence tomography (OCT) measurement or visual acuity; Glycated hemoglobin (HbA1c) of more than 10%; Monocular eyes; Epiretinal membrane; PRP within 4months before the treatment; Rubeosis iridis; Severe glaucoma; High-risk proliferative diabetic retinopathy; Poor dilation; Increased foveal avascular zone.